FDA-Approved Therapy for MS-Related Fatigue
No medication is currently FDA-approved specifically for the treatment of fatigue in multiple sclerosis. This is a critical gap in MS care, as fatigue affects over 80% of patients and can be as disabling as objective neurological deficits 1.
Off-Label Pharmacological Options
While lacking FDA approval for this indication, amantadine is the only medication with relatively sufficient evidence and is currently recommended for MS-related fatigue 1, 2. However, the clinical significance of this benefit is marginal at best.
Evidence Quality and Effect Sizes
The most recent and comprehensive network meta-analysis from 2026 3 found that compared to placebo:
- Amantadine reduced Modified Fatigue Impact Scale (MFIS) scores by 12.11 points (95% CI -14.28 to -9.94)
- Dalfampridine reduced MFIS by 14.05 points (95% CI -22.59 to -5.52)
- Methylphenidate reduced MFIS by 5.25 points (95% CI -8.44 to -2.06)
- Modafinil showed no significant difference from placebo (MD 0.60,95% CI -1.26 to 2.46)
Critical Caveat on Clinical Significance
A 2025 meta-analysis 4 provides sobering context: the pooled effect of all studied medications showed only a 3.90-point reduction in MFIS, while the minimally important difference is 4 points. The certainty of evidence was rated as low, and discontinuation due to side effects was twice as high with medications versus placebo (RR 2.11,95% CI 1.19-3.77) 4.
Practical Treatment Algorithm
First, rule out treatable causes of fatigue:
- Urinary dysfunction causing sleep disruption
- Pain or muscle spasms interfering with sleep
- Depression or mood disorders
- Medication side effects
- Sleep disorders unrelated to MS
If primary MS-related fatigue persists, consider amantadine as the first-line pharmacological option, acknowledging its modest benefit and lack of FDA approval for this indication 1, 2
Prioritize non-pharmacological interventions including:
- Structured physical activity programs
- Psychoeducational interventions
- Energy conservation strategies
- Sleep hygiene optimization
If amantadine fails or is not tolerated, dalfampridine or methylphenidate may be considered as second-line options based on recent evidence 3, though these also lack FDA approval for fatigue
Important Clinical Pitfall
Do not assume modafinil is effective despite its widespread use and theoretical mechanism. Multiple high-quality meta-analyses consistently show no significant benefit over placebo 3, 4, 1.